$Geron (GERN.US)$
Revolutionary Blood Cancer Drug RYTELO Wins European Approval: Geron's Game-Changing Treatment

$Geron (GERN.US)$
Can Geron's $47.5M RYTELO Revenue Transform This Cancer Treatment Company?

$Geron (GERN.US)$
This is a good one that works for the startegy in my opinion
Pain staking searches will always produce results. Patience is a virtue. Combining both makes for powerful decision-making
1. My strategy is to find an item that has immediate results in order to sell and recuperate the initial investment by selling 50% of the initial shares purchased. (SureBet!)
2. Leaving the remaining 50% to hit as a limit sale at the obnoxious goal minus 20% fo...

$Geron (GERN.US)$
Oh yes. I have a favorite here. Reminds me of something a long time ago
Pain staking searches will always produce results. Patience is a virtue. Combining both makes for powerful decision-making
1. My strategy is to find an item that has immediate results in order to sell and recuperate the initial investment by selling 50% of the initial shares purchased. (SureBet!)
2. Leaving the remaining 50% to hit as a limit sale at the obnoxious goal mi...

$Geron (GERN.US)$ time to sell perhaps?

$Geron (GERN.US)$ Something big is gonna happen

$Geron (GERN.US)$ Looks like have minimum 50% upside potential

$Geron (GERN.US)$ Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...

$Geron (GERN.US)$ Reuters
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis

$Geron (GERN.US)$
Almost low enough